ArticleQuantitative imaging in medicine and surgery2026
Correlations of ultrasound features and immunohistochemical indicators with axillary lymph node metastasis in invasive breast cancer.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive breast cancer (IBC) is the most common malignancy in women worldwide, and axillary lymph node status remains the strongest predictor of survival. Sentinel lymph node biopsy (SLNB) is the reference standard, but it is invasive, expensive, and carries appreciable morbidity. Reliable pre-operative, non-invasive markers are therefore urgently needed. This study aimed to investigate the correlation between ultrasound features, immunohistochemical indicators, and axillary lymph node metastasis in IBC. Methods: This study retrospectively analysed the data of 125 patients with IBC (diagnosed by preoperative core-needle biopsy or intraoperative pathology) who underwent surgical resection between January 2019 and December 2022. Patients were divided into metastatic (n=65) and non-metastatic (n=60) groups based on axillary lymph node metastasis status. Data were collected and compared. Results: Among the 125 patients, there were 26 (21%) luminal A, 58 (46%) luminal B, 20 (16%) human epidermal growth factor receptor 2 (HER2) overexpression, and 21 (17%) triple-negative types. Significant differences were found between the two groups in tumour blood flow grades (P<0.001), axillary lymph node ultrasound (P<0.001), tumour sizes (P<0.001), and Kiel-67 (Ki-67) positivity (P=0.028). Regression analysis showed that large tumour size [odds ratio (OR) =9.776; 95% confidence interval (CI): 2.111-45.266] and abnormal axillary lymph node ultrasound (OR =35.800; 95% CI: 7.637-167.846) were risk factors for metastasis. Conclusions: Tumour size, blood flow grade, Ki-67 expression, and axillary lymph node ultrasound diagnosis are correlated with axillary lymph node metastasis in IBC. Maximum tumour diameter ≥20 mm and abnormal axillary lymph node ultrasound are significant risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.